Ab­cam agrees to $5.7B sale to Dana­her amid founder's push for a board seat

Dana­her will buy Ab­cam, a re­search tools sup­pli­er re­lied up­on by many bio­phar­mas, for an en­ter­prise val­ue of about $5.7 bil­lion, the com­pa­nies an­nounced Mon­day morn­ing.

The $24-per-share deal caps a quick strate­gic al­ter­na­tives hunt for Ab­cam. In June, the board of the Cam­bridge, UK-based com­pa­ny called for a re­view, which was pre­cip­i­tat­ed by founder Jonathan Mil­ner’s at­tempt in May to re­turn to the board to fix what he called a “sus­tained pe­ri­od of op­er­a­tional un­der­per­for­mance.” Mil­ner owns 6.3% of Ab­cam.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER